Circulating CRP and calprotectin to diagnose CF pulmonary exacerbations
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (1) , 46-49
Abstract
No abstract availableKeywords
Funding Information
- BC Lung Foundation (N/A)
This publication has 11 references indexed in Scilit:
- C‐reactive protein levels in acute respiratory exacerbations of cystic fibrosisInternal Medicine Journal, 2018
- Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosisJournal of Cystic Fibrosis, 2018
- Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbationsJournal of Cystic Fibrosis, 2017
- Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic FibrosisAnnals of the American Thoracic Society, 2017
- Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometryThorax, 2015
- Measurement of Serum Calprotectin in Stable Patients Predicts Exacerbation and Lung Function Decline in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary ExacerbationsChest, 2013
- Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosisEuropean Respiratory Journal, 2011
- Sputum and serum calprotectin are useful biomarkers during CF exacerbationJournal of Cystic Fibrosis, 2010
- Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesisThorax, 2007